A recent study published in Biomedicine & Pharmacotherapy compared the efficacy and safety of regimens based on metformin in type-2 diabetes (T2D), which included placebo plus metformin and vildagliptin plus metformin. This was a network meta-analysis which selected randomized controlled trials (RCTs) from PubMed, Embase and Cochrane Library. The results exhibited that glycated hemoglobin (HbA1c) levels of T2D patients receiving vildagliptin plus metformin were comparatively lower than those receiving placebo plus metformin. Additionally, in comparison with exenatide plus metformin, the triglyceride in T2D patients who were prescribed vildagliptin plus metformin was maintained at a relatively lower level. Furthermore, the surface under the cumulative sequencing ranking curve (SUCRA) value of vildagliptin plus metformin was comparatively higher in efficacy. Therefore, it was inferred that the efficacy of vildagliptin plus metformin in patients with T2D is comparatively better.